BioSpace News Archive

Participation in event sets stage for ongoing partnerships and engagement with researchers and drug developers based in China

Cosette Pharmaceuticals, Inc., a generic pharmaceutical company primarily focused on extended topical and suppository products, announced today that it has purchased G&W Laboratories’ finished dosage manufacturing plant located in Lincolnton, NC.

Biocept, Inc. (NASDAQ: BIOC), announces that clinical data highlighting performance of the Company’s Target Selector™ tests and kits for detecting actionable oncology biomarkers will be presented at the 2019 Association for Molecular Pathology (AMP) Annual Meeting being held November 7-9,

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced that Todd Newton, CEO, and Stefanie Cavanaugh, CFO, will host investor meetings at the 10th Annual Craig-Hallum Alpha Select Conference.

SI-BONE, Inc. announced the Centers for Medicare and Medicaid Services has updated the Medicare Physician Fee Schedule for CPT® Code 27279, used to report minimally invasive sacroiliac joint fusion procedures, which are commonly performed with the iFuse Implant System®.

Ichnos Sciences announced that it has completed enrollment of two Phase 2b clinical trials for two candidates in clinical development: ISB 830, an OX40 antagonist monoclonal antibody currently in development for the treatment of atopic dermatitis, and ISC 27864, a non-opioid, potent, selective and orally bioavailable inhibitor of microsomal prostaglandin E synthase-1 currently in development for osteoarthritic pain.

CereVasc, LLC, a company focused on improving the treatment of communicating hydrocephalus patients, announced today that Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) approved the Company’s request to conduct a clinical study titled “Endovascular Treatment of Communicating Hydrocephalus with the eShunt System” (ETCHES I).

PsychoGenics Inc., announced the appointment of Mark A. Varney, Ph.D., as Chief Scientific Officer (CSO). This appointment reflects the Company’s growth in Central Nervous System (CNS) drug discovery and clinical development, and its continued commitment to the development of proprietary technologies to support internal and partnered drug discovery and translational research.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, will announce financial results for the third quarter ended September 30, 2019 on Tuesday, November 12, 2019, after the NASDAQ market close.

Fresenius Medical Care North America’s Renal Therapies Group, the leading provider of kidney care products, today announced the launch of AquaBplus and AquaC UNO H water purification systems that will be available to all dialysis centers and hospitals in North America in the first quarter of 2020.